Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Why the Middle East is being left behind by global climate finance plans 
Insignia Financial Shares Hit 3-Year High Amid Bain and CC Capital Bidding War 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
Investors Brace for Market Moves as Trump Begins Second Term 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
European Stocks Rally on Chinese Growth and Mining Merger Speculation 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Ferrari Group to Launch IPO in Amsterdam, Targets Over $1 Billion Valuation 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Home ownership is slipping out of reach. It’s time to rethink our fear of ‘forever renting’ 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
China’s Growth Faces Structural Challenges Amid Doubts Over Data 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
